| Drug Name | Oritavancin |
|---|---|
| Phase | Completed Phase III trials |
| Indication | Acute bacterial skin and skin structure infections |
| Pharmacology description/ mechanism of action | Semi-synthetic lipoglycolipopeptide, bactericidal, disrupts cell membrane and inhibits the transglycosylation and transpeptidation steps of cell wall synthesis in a dose-dependent manner |
| Route of administration | Intravenous |
| Chemical Structure |  |
| Pivotal Trial(s) | SIMPLIFI31 SOLO I29 SOLO II28 |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.